• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Damora Therapeutics (DMRA) Undervalued After Its Pullback Despite A 3.4x P/B?

    Simply Wall St·10/10/2026 16:44:40
    Listen to the news

    Damora Therapeutics (DMRA) has returned to trader screens after a sharp slide over the past few months, with recent price momentum drawing attention to its hematology-focused pipeline and premium P/B valuation.

    Over the past year, Damora Therapeutics has delivered a 66.51% total shareholder return even as its 90 day share price return declined 26.11%. This pattern points to fading near term momentum after earlier gains and a reassessment of risk around its premium P/B multiple and hematology pipeline.

    Spot under-pressure biotechs like Damora Therapeutics and compare them with 34 healthcare AI stocks that are starting to catch fresh momentum in specialist healthcare.

    After a sharp pullback but still a premium P/B and no revenue, Damora Therapeutics now asks a simple question of buyers: Does that mix still justify paying up at this valuation?

    Preferred Price-to-Book of 3.4x: Is it justified?

    Valuation on Damora Therapeutics now hinges on a P/B of 3.4x against a backdrop of no revenue and deepening losses. This puts a lot of weight on how investors rate its hematology platform and balance sheet strength rather than current earnings power.

    P/B compares the market value of the equity to its accounting book value and is often used for early-stage biopharma stocks that do not yet generate sales. For Damora Therapeutics, this lens matters because the business reports $0 in revenue, a net loss of $241.25 million and is expected to remain unprofitable over the next 3 years, so traditional earnings-based ratios like P/E are not usable.

    On a peer snapshot, the picture is mixed. Against its direct comparison set, Damora Therapeutics is described as good value with a 3.4x P/B versus a 7.5x average. This suggests the market is assigning a lower valuation to its equity than to similar companies using that yardstick. Against the broader US biotech industry though, the same 3.4x multiple is flagged as expensive relative to an industry average of 2.1x. This points to investors paying a higher price for each dollar of net assets than for many other biotech stocks.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 3.4x (ABOUT RIGHT)

    Still, Damora Therapeutics carries clear pressure points, including ongoing losses of $241.25 million and a long runway of development risk across its hematology programs.

    Find out about the key risks to this Damora Therapeutics narrative.

    Next Steps

    Mixed signals around Damora Therapeutics can feel messy, so treat this as a prompt to move fast and interrogate the underlying data yourself. The next move depends on how you weigh its 1 key reward against 1 key reward and 4 important warning signs

    Looking for more investment ideas beyond Damora Therapeutics?

    If Damora Therapeutics raises more questions than answers for your portfolio, broadening your watchlist with other targeted ideas can help you prepare your next move.

    Use the Simply Wall St screener to quickly surface opportunities that fit different risk and return profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.